Jordi Remon

30PUBLICATIONS
171CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Oct 14, 2026
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.

|Jul 28, 2026
New Treatment Strategies for Rare Genomic Alterations: EGFR Exon 20 Insertions and HER2-Deregulated Lung Cancer.

|Apr 08, 2026
Less Is More, But Me-Too Should Not Be the Strategy for Lung Cancer Treatment in 2026.

Martina Bortolot, Stephanie P L Saw, Erica Pietroluongo

|Apr 07, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Arianna Marinello, Julia K Rotow, Meghanne Lomibao

|Oct 09, 2025
Unresectable stage III non-small-cell lung cancer: state of the art and challenges.

Jordi Remon, Antonin Levy, Romane Gille

|May 16, 2025
Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.

Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia

Pageof 5

Frequent Collaborators

8 joint publications

Benjamin Besse

7 joint publications

Lizza Hendriks

5 joint publications

Mihaela Aldea

4 joint publications

David Planchard